Lymphatic system

Global $8.4 Bn Intravenous Infusion Pumps (Volumetric, Insulin, Syringe, Enteral, Ambulatory, Implantable Pumps) Markets Analysis & Forecasts, 2016-2020 & 2021-2028 - ResearchAndMarkets.com

Thursday, November 25, 2021 - 4:10pm

The "Global Intravenous Infusion Pumps Market Report 2021-2028" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Intravenous Infusion Pumps Market Report 2021-2028" has been added to ResearchAndMarkets.com's offering.
  • According to a study conducted by Mindray Medical Company in 2018, medical pumps are the most conventional hospital rentals equipment.
  • FDA also launched a website that gives peculiar information about medical pumps to the patients, users, and other stakeholders.
  • Chapter 3 Intravenous Infusion Pump Market: Variables, Trends, & Scope
    Chapter 4 Intravenous Infusion Pumps Market: Product Segment Analysis
    4.1.1.1 Volumetric Infusion Pumps market, 2016 - 2028 (USD Million)

Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer

Thursday, November 25, 2021 - 8:00am

DUBLIN, Nov. 25, 2021 /PRNewswire/ --Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer.

Key Points: 
  • DUBLIN, Nov. 25, 2021 /PRNewswire/ --Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer.
  • "The breadth of knowledge Elisabeth has gained working at Celgene, alongside her extensive clinical experience, makes her a crucial addition to our team," said Florent Gros, Co-Founder and CEO of Priothera.
  • "I am pleased to join Priothera at such an important stage of its development," said Dr. Kueenburg.
  • Dr. Kueenburg brings significant drug development and medical affairs experience from her years at Celgene where she most recently served as Clinical Development Lead.

Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer

Thursday, November 25, 2021 - 8:00am

DUBLIN, Nov. 25, 2021 /PRNewswire/ -- Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer. Dr. Kueenburg will lead the advancement of mocravimod into Phase 2b/3 clinical trials as a potential treatment for patients with Acute Myeloid Leukemia (AML) receiving hematopoietic stem cell transplantation (HSCT), and expansion of Priothera's pipeline.

Key Points: 
  • Dr. Kueenburg, former Clinical Development Lead at Celgene, a Bristol Myers Squibb Company, to advance clinical development of mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic stem cell transplant
    DUBLIN, Nov. 25, 2021 /PRNewswire/ --Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer.
  • "The breadth of knowledge Elisabeth has gained working at Celgene, alongside her extensive clinical experience, makes her a crucial addition to our team," said Florent Gros, Co-Founder and CEO of Priothera.
  • "I am pleased to join Priothera at such an important stage of its development," said Dr. Kueenburg.
  • Dr. Kueenburg brings significant drug development and medical affairs experience from her years at Celgene where she most recently served as Clinical Development Lead.

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML

Tuesday, November 23, 2021 - 9:30pm

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML).

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML).
  • Apollomics Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study.
  • The trial will enroll approximately 140 adult patients with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy.
  • Apollomics expects to conduct this study at approximately 20 blood cancer clinical research centers across China.

IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference

Tuesday, November 23, 2021 - 1:05pm

IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that IMVs executive management team will be participating in the upcoming Piper Sandler Virtual Healthcare Conference.

Key Points: 
  • IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that IMVs executive management team will be participating in the upcoming Piper Sandler Virtual Healthcare Conference.
  • Actual conference: November 30 - December 2, 2021
    A webcast of this presentation will be accessible in the 'Events, Webcasts & Presentations' section of IMVs website .
  • IMV is also developing another DPX-based immunotherapy: DPX-SurMAGE, a dual targeted immunotherapy being evaluated in patients with bladder cancer.
  • IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

$3.94 Bn Hematology Analyzer Markets - Global Opportunity Analysis and Industry Forecast, 2021-2030. - ResearchAndMarkets.com

Tuesday, November 23, 2021 - 12:20pm

The "Hematology Analyzer Market by Product & Service, Type and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030."

Key Points: 
  • The "Hematology Analyzer Market by Product & Service, Type and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030."
  • The global hematology analyzer market was valued at $1,962.40 million in 2020 and is projected to reach $3,941.10 million by 2030 registering a CAGR of 7.30% from 2021 to 2030.
  • In addition, technological advancements in hematology analyzers, and growth in demand for automated hematology analyzer coupled with rising preference towards high sensitivity hematology analyzer further boost the growth of the hematology analyzer market.
  • In contrast, growth opportunities in emerging economics expected to offer lucrative growth opportunities for players in the hematology analyzer market.

iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December

Tuesday, November 23, 2021 - 7:00am

iOnctura SA is clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.

Key Points: 
  • iOnctura SA is clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.
  • iOncturas best-in-class drug development programs combine immune-mediated and direct anti-tumour activity to deliver molecules with superior clinical efficacy and safety in oncology.
  • iOnctura is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.
  • iOnctura has undertaken extensive validation of the autotaxin inhibition mechanism in multiple preclinical solid tumor models.

InsightRX's Precision Medicine Technology to Help Improve Care for Patients Receiving Stem Cell Transplants

Monday, November 22, 2021 - 5:15pm

The InsightRX Nova platform helps to select patient-specific doses of the chemotherapy drugs busulfan and fludarabine, as well as the immunosuppressant anti-thymocyte globulin (ATG), for adult and pediatric patients receiving stem cell transplants.

Key Points: 
  • The InsightRX Nova platform helps to select patient-specific doses of the chemotherapy drugs busulfan and fludarabine, as well as the immunosuppressant anti-thymocyte globulin (ATG), for adult and pediatric patients receiving stem cell transplants.
  • Stem cell transplants typically are preceded by a chemotherapeutic conditioning regimen that destroys cancer cells and suppresses a patient's immune response to the donor cells.
  • The five-year cumulative mortality rate for leukemia patients receiving a stem cell transplant is about 50%, with relapse, infection, and GvHD as the leading causes of death.
  • InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Monday, November 22, 2021 - 1:40am

"AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.

Key Points: 
  • "AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
  • This combined treatment approach could have a meaningful impact on the lives of patients living with relapsed or refractory AML."
  • The Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study.
  • The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for the treatment of adults with relapsed or refractory acute myeloid leukemia.

Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements

Monday, November 22, 2021 - 1:00pm

By decision dated August 9, 2021, the Panel granted the Company an exception through November 22, 2021, to complete the merger with Biosight and evidence compliance with all applicable initial listing criteria.

Key Points: 
  • By decision dated August 9, 2021, the Panel granted the Company an exception through November 22, 2021, to complete the merger with Biosight and evidence compliance with all applicable initial listing criteria.
  • Pursuant to the Nasdaq Listing Rules, the combined company will be required to meet all applicable initial listing requirements for The Nasdaq Capital Market upon the closing of the merger, including the $4 per share price requirement.
  • While there can be no assurance, the Company believes that it will be able to close the merger and demonstrate compliance with all applicable requirements for initial listing on The Nasdaq Capital Market on or before December 20, 2021.
  • The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made.